SBRT is a unique modality of radiation treatment. Typically, radiation therapy is delivered in many small doses called fractions (often 40 or more), but studies have been created to explore the possiblity of delivering radiation in fewer, larger doses. This article covers two studies, examining the outcome of hypofractionated (fewer fractions) treatment delivered by SBRT.
Viewing entries tagged
Novel Agent Being Explored in Two Trials of High-Risk Prostate Cancer | An Article by Dr. Berberabe for Cure Magazine
"Researchers are hopeful about the potential for a novel agent in high-risk prostate cancer" states Tony Berberabe, MPh in his published article for Cure Magazine on June 23rd, 2016
Selecting a treatment for prostate cancer is increasingly complex. In an effort to help my prostate cancer patients navigate the complexities of this process, I routinely frame the discussion around these three rules:
Rule #1: If you listen to enough people you will hear just about anything.
Radium-223 (Alpharadin) A Novel Targeted Alpha-Emitter for Bone-Metastatic Castrate-Resistant Prostate Cancer
Radium-223 (or Alpharadin) is a new targeted alpha-emitting agent which has shown a prolongation of survival in castrate-resistant prostate cancer patients with bone-metastatic disease (5).